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ABSTRACT
Objective To compare the effectiveness of the mobile 
e- Tabac Info Service (e- TIS) application (app) for helping 
adult smokers quit smoking with current practices.
Design Pragmatic randomised controlled trial with a 1- 
year follow- up (2017–2018).
Setting France, population- wide level.
Participants 2806 adult smokers who wished to quit 
smoking were recruited via the website of the French 
National Mandatory Health Insurance fund. Of them, 1400 
were randomised to the e- TIS app arm and 1406 were 
randomised to the current practices arm (control).
Intervention The app involved personalised interactive 
contacts that included questionnaires, advice, activities 
and text messages. All contacts were individually tailored 
and based on each smoker’s progress.
In the control group, recommended practices for quitting 
smoking were described on a non- interactive website.
Primary and secondary outcomes measures The 
primary outcome was 7- day point prevalence abstinence 
(PPA) at 6 months. The secondary outcomes included 
continuous abstinence rates at 6 and 12 months, minimum 
24- hour point abstinence at 3 months, minimum 30- day 
point abstinence at 12 months and number and duration of 
quit attempts.
Results There was no difference between the e- TIS and 
control arms for the primary outcome (12.6% vs 13.7% 
for 7- day PPA at 6 months, p=0.3949, intention- to- treat 
analysis). However, e- TIS participants with high levels of 
exposure to the app, which was defined by the completion 
of at least eight activities or questionnaires, showed higher 
rates of smoking cessation than the control participants 
(17.6% vs 12.9% for 7- day PPA at 6 months, p=0.0169, 
per- protocol analysis).
Conclusion Use of the e- TIS app was not associated with 
a higher rate of smoking cessation. However, high level of 
exposure to the e- TIS app may have been more effective 
than current practices.
Trial registration number NCT02841683.
INTRODUCTION
Smoking remains a leading risk factor for 
early death and disability.1 Thus, there is 
a need to strengthen support for smoking 
cessation. In this context, mobile phone 
applications (apps) are increasingly used and 
have several advantages in terms of their inex-
pensiveness, scalability to large populations, 
interactivity, ability to be used anywhere at 
any time, to be tailored to individual users, 
to distract smokers from cravings and to link 
users with social support.2 Although several 
apps for smoking cessation are available only 
a few are theory or evidence based.3 4 None-
theless, these health apps appear to be used 
more effectively and for longer periods of 
time when they offer support that extends 
beyond motivation maintenance and contri-
butions to self- knowledge.5
In France, a theory- based app for smoking 
cessation, the e- intervention Tabac Info 
Service (e- TIS), has been developed by 
Santé publique France and the Caisse natio-
nale d’assurance maladie.6 This app was 
designed to provide support to smokers who 
wish to quit, including those who are not 
currently involved in a quit attempt, and 
was based on the effectiveness criteria of 
online programmes7 and psychosocial and 
behavioural change theories.8–12 The e- TIS 
app provides tailored activities, self- report 
exercises, tips, social and/or psychological 
support, reassurance and motivational text 
messages that are adapted to the individual 
Strengths and limitations of this study
 ► This was a large, national, randomised controlled 
trial.
 ► This was a pragmatic trial that was conducted under 
‘real- life’ conditions.
 ► According to guidelines, the primary outcome was 
point prevalence abstinence at 6 months.
 ► The main limitation of the study is the high attrition 
rate.
 ► Findings may have been influenced by contamina-
tion between arms due to the unrestricted availabili-
ty of the e- Tabac Info Service from app stores during 
the trial.
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characteristics of the user.13 The present study evaluated 
the effectiveness of the theory- based smoking cessation 
e- TIS app in a pragmatic randomised controlled trial 
conducted in France on a population- wide level.
METHODS
This manuscript was written in accordance with the 
Consolidated Standards of Reporting Trials Statement 
and the EHEALTH checklist.14
Study design
The protocol was previously registered (NCT02841683) 
and published.13 Participants were randomly assigned 
(1:1) to either the intervention arm (invitation to use 
the e- TIS app) or the control arm (current practices for 
smoking cessation described on a non- interactive website 
from the French National Mandatory Health Insurance ( 
ameli. fr)). The current practices were based on the guide-
lines of the Haute Autorité de Santé.15 All participants 
were recruited between February 2017 and April 2018, 
then followed up over the subsequent 1- year period.
All participants consented to inclusion in the study and 
an automated randomisation procedure was carried out 
following the receipt of all inclusion data. A minimisa-
tion software package was employed to reduce the risk of 
unmatched groups and to stratify the participants based 
on age and sex, using the following parameters: study arm 
(e- TIS and control, allocated 50/50), sex (male/female) 
and age (≤45 years or >45 years).
Study population and sample
When visiting their personal account on the French 
Mandatory National Health Insurance website, users were 
invited to participate in the present study via a banner. 
Users who clicked on the banner were presented with 
an information sheet, which included a section where 
they could provide informed consent. The consent form 
contained the inclusion questionnaire, with the following 
criteria: (1) adult smoker; (2) completion of the online 
consent form; (3) agreement to participate in the 
study; (4) possession of a mobile phone using an iOS or 
Android system; (5) willingness to use the app; and (6) 
attempt or consideration of an attempt to quit smoking. 
If the user provided consent to be enrolled in the study, 
they were sent an email with a confirmation link. When 
the participants clicked the confirmation link, they were 
randomised and invited to fill in the entry questionnaire 
(T0) for the study.
Intervention arm: e-TIS app
Participants assigned to the intervention arm were invited 
to download the e- TIS app. In accordance with the relapse 
prevention model,16 17 the e- TIS app is tailored to each 
individual smoker based on feedback. Furthermore, the 
support process in the e- TIS is based on the efficacy criteria 
of online programmes, which include the frequency and 
intensity of contacts, short messages, interactivity, appeal, 
personalisation, credibility of content and sharing func-
tions,7 as well as various theoretical models that are used 
for withdrawal treatments.8–12 18
The e- TIS app involves personalised interactive (push) 
contacts that include questionnaires, activities and text 
messages which are available via mobile phone, the 
website platform and tablets. In total, the intervention 
consists of 16 different activities, eight position ques-
tionnaires (to adapt the app content to the evolution of 
one’s willingness to quit or attempt to quit), and a set of 
roughly 170 email or push- app text messages/notifica-
tions with distinct purposes. All contacts are tailored to 
the answers on the eight position questionnaires and an 
individual’s progress through the four modules of the 
app. Each participant began the process within a module 
that was adapted to his/her individual stage regarding 
tobacco status. The content has been described in detail 
elsewhere.13 The present study evaluated e- TIS V.2.0.
Control arm: current practices
Participants assigned to the control arm were invited to 
visit a pre- existing website page that listed smoking cessa-
tion resources that are readily available in France and 
recommended by the Haute Autorité de Santé.15
Outcomes and other data
The primary outcome in the present study was point prev-
alence abstinence (PPA) at the 6- month follow- up assess-
ment. The PPA for smoking is a minimum of 7 days.19 In 
general, the PPA is considered to be the most appropriate 
measure for evaluating abstinence in intervention evalu-
ation studies.20
Because a large number of participants were lost to 
follow- up during the study, and due to the need to limit 
the amount of missing data, the original study protocol 
was modified as follows before the blinding was lifted: 
(1) for participants with information regarding smoking 
status at 12 months but not at 6 months, the 12- month 
smoking status was used to replace the missing data 
regarding smoking status at 6 months; (2) for participants 
with information regarding smoking status at 3 months 
but not at 6 or 12 months, the 3- month smoking status 
was used to replace the missing data regarding smoking 
status at 6 months. Additionally, at the 6- month follow- up 
assessment, participants with missing data were phoned 
and reminded of the study. This recalculated criterion 
was used as the primary outcome. Sensitivity analyses were 
performed with the original criterion (ie, without imputa-
tions for missing data).
Based on previous data and recommendations,2 7 20 21 
the secondary outcomes in the present study included 
continuous abstinence at 6 months, continuous absti-
nence at 12 months, minimum 24- hour point abstinence 
at 3 months, minimum 30- day point abstinence at 12 
months and number and duration of quit attempts. To 
further characterise tobacco consumption, the present 
study also collected data associated with the dependency 
and determinants of abstinence, described elsewhere.13
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Data collection
Data were collected via internet- based self- report ques-
tionnaires at inclusion (technical variables), study initia-
tion (initial self- reporting questionnaire) and at 3, 6 and 
12 months (three follow- up self- report questionnaires). 
Application usage data were extracted from the applica-
tion database and a match with the study data measured 




The required sample size was calculated based on the 
hypothesis of a 10% abstinence rate at 6- month follow- up 
in the control group.22 Given this rate, sample sizes of 
1500 participants per group were necessary to show a 
minimum OR of 1.5 with a power of 90% (α=0.05, bilat-
eral test); thus, a total sample size of 3000 individuals was 
necessary.23
Statistical methods
Statistical analyses were performed for the intention- 
to- treat (ITT), per- protocol (PP) and as- treated (AT) 
populations. The ITT analysis included all participants in 
the arms to which they were randomised, regardless of 
adherence to the prescribed intervention. For the PP and 
AT analyses, exposure to the application was defined as 
the completion of at least one activity or questionnaire 
through the app. For the PP analysis, participants in 
the intervention arm were defined as those randomised 
to that arm who completed at least one activity or ques-
tionnaire. Participants in the control arm were defined 
as those randomised to that arm who did not complete 
any activities or questionnaires through the app. For 
the AT analysis, participants who completed at least one 
activity or questionnaire through the app, independent 
of their allocation arm, were regarded as those exposed 
to the intervention. Participants who did not complete 
any activities or questionnaires through the application, 
independent of their allocation arm, were regarded as 
non- exposed to the intervention.
For the main analysis, participants lost to follow- up 
(those who did not answer the questionnaires) were 
defined as smokers, as previously recommended,7 21 24 
whereas the secondary analysis only considered partici-
pants who were not lost to follow- up. Multivariate anal-
yses, adjusted for baseline characteristics, were performed 
in the PP and AT populations. To compare the effects of 
the e- TIS app on smoking cessation in terms of low versus 
high levels of e- TIS use, participants were categorised 
based on median use in the present study: that is, the 
completion of eight activities or questionnaires through 
the app.
Some subgroup analyses were conducted as defined 
in the study protocol.13 Other subgroup analyses were 
added to the initial protocol (before the blinding was 
lifted): tobacco status at inclusion and plans to have or 
adopt a child in the following year. Sensitivity analyses 
were performed using only data from participants with a 
smoking status at 6 months, without data recovery based 
on 3- month and/or 12- month smoking status. All statis-
tical analyses were performed in 2019 using SAS V.9.4 
Software (SAS Institute).
Patient and public involvement
Patients or the public were not involved in the design, or 
conduct, or reporting, or dissemination of our research.
RESULTS
Recruitment and baseline characteristics
Figure 1 displays the flow chart of the randomisation and 
follow- up procedures. A total of 2806 participants with 
inclusion data were randomised for the present study; 
of these, 1400 were allocated to the e- TIS arm and 1406 
were allocated to the control arm. Based on the recovery 
of missing data, 518 and 602 participants were followed 
up at 6 months in the e- TIS and control arms, respec-
tively. Figure 1 shows contamination between the groups. 
Specifically, of the 1400 participants in the e- TIS arm, 
787 were exposed to the app, whereas 613 participants 
were considered to not have been exposed to the app; 
the 3- month and 6- month usage rates for the app were 
10.7% and 5.7%, respectively. Of the 1406 participants 
in the control arm, 1127 participants were not exposed 
to the app, whereas 279 participants were considered to 
have been exposed to the app. The ITT, PP and AT popu-
lations used to assess the primary outcome at 6 months in 
each arm are displayed in figure 1.
The baseline characteristics of the participants and 
their exposure levels to the e- TIS app are presented in 
online supplemental table 1. Of the total participants, 
most were women, aged 45 years or younger, and current 
smokers. There were no significant differences between 
the groups at baseline.
Primary outcome
There were no differences in PPA at 6 months between 
the e- TIS and control arms in the ITT, PP and AT popu-
lations (table 1). When considering only respondents in 
the total population, 32.9% and 32.4% of participants 
were quitters in the ITT/AT and PP populations, respec-
tively. When considering non- respondents as smokers, 
13.1% and 12.9% of the participants, respectively, were 
quitters. There were no significant differences in the 
primary outcome between participants exposed to the 
e- TIS and participants not exposed to e- TIS in the PP and 
AT populations (table 2).
Secondary outcomes
There were no significant differences in any of the 
secondary outcomes between the e- TIS and control arms 
in the ITT population (online supplemental table 2).
High level of e-TIS use
Table 3 presents the group differences in the primary 
outcome in the PP and AT populations after considering 
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exposure to the e- TIS. In the PP population when consid-
ering non- respondents as smokers, 17.6% of partici-
pants in the e- TIS high exposure group were quitters, 
compared with 12.9% in the control group (p=0.0169). 
In the AT population when considering non- respondents 
as smokers, 18.2% of the participants in the e- TIS high 
exposure group were quitters, compared with 11.8% in 
the other group (p<0.0001).
Sensitivity analysis
Sensitivity analyses were performed using participants 
with data at 6 months (no recovery data were used); 
online supplemental figure 1 presents the corresponding 
diagram flow. These results were similar to those of the 
main analysis (online supplemental table 3).
Subgroup analyses
Online supplementary figure 2 illustrates the subgroup 
analyses performed using the ITT population, which 
considered non- respondents as smokers. There were no 
differences in the minimum 7- day PPA between the e- TIS 
and control arms in any of the identified subgroups.
Similar results were obtained in the ITT population 
when only respondents were considered, as well as in 
the PP and AT populations (both cases: non- respondents 
were considered as smokers and only considering respon-
dents) with the following exceptions (online supplemental 
table 4 a–r). In the AT population and among smokers 
at inclusion, quitters were overrepresented among the 
e- TIS participants, relative to participants who were 
not exposed to the e- TIS. Therefore, when considering 
non- respondents as smokers, 11.2% (n=80) of the e- TIS 
participants were quitters, compared with 8.0% (n=93) 
of the participants who were not exposed to the e- TIS 
(p=0.0193). Similar results were obtained when analyses 
were performed using participants with no recovery data 
at 6 months in the ITT, PP and AT populations.
DISCUSSION
The present study evaluated the effectiveness of the 
theory- based smoking cessation e- TIS app. This study was a 
randomised controlled trial under pragmatic conditions, 
which enabled evaluation of the effectiveness of e- TIS in 
real- life situations. The pragmatic situation is particularly 
relevant for behaviour change interventions.25 Indeed, 
for these interventions, determinants of choice to partic-
ipate in the trial may also be determinants of outcome 
(eg, motivation). This type of intervention may thus have 
more favourable results within a trial than in a real- life 
situation.13 It is to limit this major bias that we wanted the 
inclusion procedure to be the lightest possible in order 
to recruit smokers who were not selected because of their 
high motivation to participate in a trial. The major disad-
vantage of this methodological choice is the high attrition 
Figure 1 Diagram depicting the flow of participants in the study (n=2806). AT, as- treated; e- TIS, e- intervention Tabac Info 
Service; ITT, intention- to- treat; PP, per- protocol.
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rate we observed. Although a high rate of attrition is quite 
common in investigations of mHealth tools,26 27 ours is 
particularly high.
Moreover, the present findings may have been influ-
enced by high levels of contamination between the study 
arms due to the unrestricted availability of the e- TIS from 
app stores during the trial. Our results according to the 
three types of analysis (ie, ITT, PP, AT) are consistent, 
which is in favour of the robustness of our results in this 
regard.
The primary outcome was PPA at 6 months. This is the 
recommended duration. It is justified by the high rate 
of short- term relapse during smoking cessation.24 PPA is 
considered to be the most appropriate measure for evalu-
ating abstinence in intervention evaluation studies.20 The 
continuous abstinence, recommended in clinical trials,24 
Table 1 Between- group differences in the primary outcome (minimum of 7- day point prevalence abstinence (PPA) at 6 








P value*n % n % n %
Minimum of 7- day PPA at 6 
months (n=1120)†
0.4593
Smokers 752 67.1 342 66 410 68.1
Quitters 368 32.9 176 34 192 31.9
Minimum of 7- day PPA at 6 
months (n=2806)‡
0.3949
Smokers 2438 86.9 1224 87.4 1214 86.3








P value*n % n % n %
Minimum of 7- day PPA at 6 
months (n=759)†
0.2196
Smokers 513 67.6 191 65 322 69.2
Quitters 246 32.4 103 35 143 30.8
Minimum of 7- day PPA at 6 
months (n=1914)‡
0.7974
Smokers 1668 87.1 684 86.9 984 87.3







Non- exposure to e- TIS
n=1740 (62.0%)
P value*n % n % n %
Minimum of 7- day PPA at 6 
months (n=1120)†
0.1745
Smokers 752 67.1 279 64.7 473 68.7
Quitters 368 32.9 152 35.3 216 31.3
Minimum of 7- day PPA at 6 
months (n=2806)‡
0.1599
Smokers 2438 86.9 914 85.7 1524 87.6
Quitters 368 13.1 152 14.3 216 12.4
*χ2 test.
†Only respondents considered.
‡Non- respondents considered as smokers.
e- TIS, e- intervention Tabac Info Service.









pen: first published as 10.1136/bm





6 Affret A, et al. BMJ Open 2020;10:e039515. doi:10.1136/bmjopen-2020-039515
Open access 
is not relevant in this context because a planned cessation 
date was not a criterion for inclusion and patients could 
stop smoking at any time during follow- up. However, 
we have retained it as a secondary outcome and results 
remained unchanged with this outcome. Similarly, our 
imputation procedures to account for missing data did 
not change results as shown in sensitivity analyses.
Because the trial is not conclusive given its limita-
tions and because the present results may be explained 
by multiple hypotheses, the next step of our study will 
consist of the performance of a process evaluation28 using 
behavioural change techniques taxonomy,29 30 in order to 
better understand the e- TIS mechanisms and conditions 
of efficacy. These conditions relate to the participants; 
the different components of e- TIS used by the partici-
pants; the psychological, social and environmental factors 
possibly affecting the participants during the study.13
As expected, the participants were mostly young and 
had a high level of education,31 which is consistent with 
the nature of the digital intervention.32 Furthermore, 
more women agreed to participate. Similar rates of 
female participants were observed in the trials reviewed 
by Whittaker et al2 that employed similar methods of 
inclusion.33–35
The present study also revealed a high rate of smoking 
cessation among all participants. Notably, the rates 
observed in this study were higher than those in a previous 
French trial that evaluated the previous TIS modality, 
which employed email coaching (32.9% in present study 
vs 24.7%).36 When considering non- respondents as 
smokers, 12.6% and 13.7% of participants in the e- TIS and 
control arms, respectively, were quitters. Previous studies 
have reported that 9% of intervention group populations 
and 5%–6% of control group populations are quitters.2 It 
is important to note that the control arm in the present 
study may not have been considered a true control arm; 
importantly, the original e- TIS protocol submitted to the 
ethical committee planned to compare the e- TIS arm with 
a control arm (no intervention other than standard prac-
tices). However, the committee suggested that the control 
participants be exposed to best evidence- based practices 
currently in use.15 Thus, the Quitting page of the French 
National Mandatory Health Insurance website (Ameli) 
was suggested to the control participants, and some of 
these participants may have used the various smoking 
cessation resources which are all considered to be effec-
tive. For example, at 6 months, 36.4% of participants in 
the control arm had used nicotine replacement therapies 
within the previous 3 months.
The present study also revealed a lack of differences 
between the e- TIS and control arms in the ITT, PP and AT 
populations. In a Cochrane systematic review conducted 
Table 2 Minimum of 7- day point prevalence abstinence (PPA) in the per- protocol (PP) and as- treated (AT) populations 
(multivariate analysis)
Minimum 7- day PPA at 6 
months Multivariate regression*




Only considering respondents (n=743/759†)‡ 0.214
  Control 453 138 30.5 1
  e- TIS exposure 290 102 35.2 1.22 0.89 1.67
Considering non- respondents as smokers (n=1831/1914†)§ 0.6689
  Non- exposure to e- TIS 1080 132 12.2 1
  e- TIS exposure 751 99 13.2 1.06 0.8 1.41
AT population
Only considering respondents (n=1095/11202†)‡ 0.1882
  Non- exposure to e- TIS 671 210 31.3 1
  e- TIS exposure 424 150 35.4 1.19 0.92 1.54
Considering non- respondents as smokers (n=2679/28062)§ 0.1449
  Non- exposure to e- TIS 1660 202 12.2 1
  e- TIS exposure 1019 146 14.3 1.19 0.94 1.49
*Adjusted for baseline characteristics, with the exception of tobacco status at inclusion. The stepwise variable selection method was used 
with an input threshold in the model at 0.2 and an output threshold in the model at 0.05. Only factors with a significant association with the 
0.2 threshold in the bivariate model were candidates in the multivariate model.
†Due to missing data regarding the variables considered in the multivariate model.
‡Retained variables: expecting a child.
§Retained variables: family situation, level of education, treatment for cardiovascular or respiratory diseases.
e- TIS, e- intervention Tabac Info Service.
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in 2014, Whittaker et al2 concluded that mobile phone- 
based smoking cessation interventions had a beneficial 
impact on 6- month outcomes (relative risk: 1.67, 95% CI 
1.46 to 1.90; I2=59%; 12 studies included). However, most 
studies included in that review employed short message 
service text messaging- based interventions, rather than 
complex apps; notably, more complex apps use text 
messaging and other forms of contact. Therefore, direct 
comparisons between these results may be inappropriate.
Similar to the findings of recent studies that investi-
gated the effectiveness of complex apps,37 38 the present 
results showed that the results in the intervention and 
control arms did not differ at 6 months. Baskerville et 
al37 compared the effectiveness of an evidence- informed 
self- help guide with a non- intervention arm, which may 
explain the absence of differences in both arms, and 
Garrison et al.38 evaluated a mindfulness training app. 
Although there were no group differences in smoking 
abstinence at 6 months, the intervention app reduced 
the associations between craving and smoking, compared 
with the control app. In contrast, BinDhim et al39 
reported that individuals exposed to a smartphone- based 
decision aid were significantly more likely to exhibit 
continuous abstinence at 6 months than those exposed to 
an information- only app. In that study, the intervention 
app was required to display information regarding quit-
ting options, whereas the control app was not required to 
display this information.
Furthermore, Brown et al22 found that the StopAdvisor 
app was more effective than an information- only website 
for helping participants with a low socioeconomic status 
stop smoking; it is important to note that this study was 
designed with sufficient power to separately assess effec-
tiveness within each socioeconomic status subsample. In 
the present study, there were no differences according 
to socioeconomic status, based on the reported level of 
education. Additionally, in the StopAdvisor study, the 
authors noted that the control website was used less regu-
larly than the StopAdvisor website in terms of logins, 
page views and time spent on the website. At the 6- month 
follow- up assessment in the present study, several of 
the control participants reported that they had been 
using other forms of smoking cessation support in the 
three previous months (eg, use of nicotine replacement 
Table 3 Between- group differences in the primary outcome in the per- protocol (PP) and as- treated (AT) populations, which 








P value*n % n % n %
Minimum 7- day PPA at 6 months (n=704)‡ 0.0139
Smokers 472 67 106 59.6 366 69.6
Quitters 232 33 72 40.4 160 30.4
Minimum 7- day PPA at 6 months 
(n=1652)‡
0.0169
Smokers 1420 86 337 82.4 1083 87.1






Non- exposure to 
e- TIS
n=2234 (79.60%)
P value*n % n % n %
Minimum 7- day PPA at 6 months 
(n=1120)‡
0.0018
Smokers 752 67.1 150 59.1 602 69.5
Quitters 368 32.9 104 40.9 264 30.5
Minimum 7- day PPA at 6 months 
(n=2806)§
<0.0001
Smokers 2438 86.9 468 81.8 1970 88.2
Quitters 368 13.1 104 18.2 264 11.8
*χ2 test.
†Completed at least eight activities or questionnaires through the application.
‡Only respondents considered.
§Non- respondents considered as smokers.
e- TIS, e- intervention Tabac Info Service; PPA, point prevalence abstinence.
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therapies and/or consultation with a healthcare profes-
sional). This could explain the high smoking cessation 
rate in the present control group (13.7%) versus that in 
the StopAdvisor study (10%).
Moreover, the effects of health apps remain contro-
versial because they are influenced by numerous factors 
related to the app components, characteristics of the users 
(eg, motivation, previous attempts to quit, and unifor-
mity) and the environment of the participant (eg, social 
support). As a result, some authors have advocated for 
the use of process evaluations to complement the effec-
tiveness evaluations when assessing this ‘black box’.5 40 41
The present study also found that the numbers of quit-
ters in the PP and AT populations at 6 months were higher 
among participants exposed to the e- TIS, compared 
with those not exposed to the app, when e- TIS exposure 
was defined as the completion of at least eight activi-
ties and/or questionnaires (ie, the median exposure). 
It is tempting to conclude that the e- TIS was effective if 
used intensively, which would be consistent with previous 
results on the relationship between use frequency and 
efficacy.5 42 However, it is likely that the most motivated 
participants used the app for a longer time; this motiva-
tion, rather than the duration or frequency of use, would 
have improved the results. This idea is consistent with the 
findings of prior studies, in which the most motivated 
people were those who used the apps more frequently.5 43 
In the same way, it is possible that it is a feedback loop 
between engagement and effectiveness.44 However, in our 
population, there is no relationship between motivation 
at inclusion and subsequent use (data not shown), which 
is an argument for the effectiveness of exposure to the 
application. That remains to be confirmed.
CONCLUSIONS
In the present study, use of the e- TIS app was not associ-
ated with a higher rate of smoking cessation. However, 
high level of exposure to the e- TIS app may have been 
more effective than current practices.
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